Mira Kyivska

Moderna announces detailed positive Phase 3 study results: Can MRNA break above $198.48?

Moderna announces detailed positive Phase 3 study results: Can MRNA break above $198.48?
Moderna stock falls 19.3% today

Moderna announced detailed positive results from a Phase 3 study of its investigational mRNA-based individualized neoantigen therapy, intismeran autogene, evaluated in combination with Merck's KEYTRUDA. The stock is down 19.3% on the day at $198.34.

MRNA price prediction
24H 0.81%
$198.39
48H 0.8%
$198.36
7D -2.12%
$192.61
1M 14.53%
$225.38
3M 41.83%
$279.11
6M 129.94%
$452.5
12M 344.24%
$874.22
Current price: $196.79 -10.0100 4.84%
Closed 11/18
Daily range 196.52 Arrow from to Icon 208.68
Weekly range 196.52 Arrow from to Icon 245.28
Loading...

Highlights

  • Moderna reported positive Phase 3 results for its mRNA-based individualized neoantigen therapy intismeran autogene combined with KEYTRUDA.
  • Shares of Moderna are down 19.3% on the day at $198.34.
  • Of 92 analysts covering Moderna, 19 rate the stock a buy, 11 recommend selling, and the median price target is $125.

Moderna announced detailed positive results from the Phase 3 INTerpath-001 study evaluating intismeran autogene, also known as mRNA-4157 or V940. The investigational mRNA-based individualized neoantigen therapy was evaluated in combination with KEYTRUDA, Merck's anti-PD-1 therapy. The announcement was made by the company.

Resistance meets mixed chart signals as daily structure splits

Price is sitting right at resistance from the Ichimoku Kijun at $198.48. Shares of Moderna show a split daily structure, with price below the MA-20 but above the MA-50 and MA-200. RSI at 68.6 is nearing overbought territory, an early indication the recent advance may be getting stretched.

Upside odds dominant as buyers eye a close above resistance

A close above $198.48 would show buyers are willing to follow through. During the session, Moderna stock lost the MA-20 at $209.51 after previously closing above it. Even so, over the next five trading days, the upside probability is more than 80% and the downside probability is less than 20%, with an expected trading range of $178.16 to $218.51. A drop below $165.45 would show the move is being faded. On the weekly chart the longer-term picture stays firmly constructive.

Earlier, analysts noted that Moderna's technical strength and institutional interest were supported by its upcoming inclusion in the Nasdaq-100. The latest clinical update and subsequent price action now shift focus to whether shares can sustain above $198.48, with the next decisive move likely to set the immediate trading range between $178.16 and $218.51.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.